A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Corvus goes pivotal in peripheral T-cell lymphoma
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
